Atricure Stock Price, News & Analysis

AtriCure has announced its preliminary financial results for Q4 and full year 2024, alongside its 2025 financial guidance.

Preliminary, unaudited revenue for Q4 2024 is expected to be $124.3 million, a growth of approximately 17% over Q4 2023. U.S. revenue is projected at $101.6 million (14% growth), and international revenue at $22.7 million (28% growth). This growth is driven by strong performance in cryoSPHERE® devices, AtriClip® devices, and the EnCompass® clamp.

For the full year 2024, revenue is expected to be $465.3 million, up by 17% from 2023. Adjusted EBITDA is anticipated to be around $26 million to $29 million, with an adjusted loss per share of $0.74 to $0.80.

Looking ahead, AtriCure projects 2025 revenue between $517 million and $527 million, with positive adjusted EBITDA of $40 million to $44 million and modest cash flow generation. The company will host an Analyst & Investor Day on March 26, 2025, to discuss its product portfolio, innovative pipeline, and long-term financial goals.

AtriCure (Nasdaq: ATRC), a leader in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

The event will take place on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. AtriCure’s management will present at this conference. Interested individuals can access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management will engage in a fireside discussion on Wednesday, December 4, 2024, at 9:00 am EST. The presentation will be accessible via live audio webcast through the Investors section of AtriCure's website.

AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Stifel 2024 Healthcare Conference. The company's management will engage in a fireside chat on Monday, November 18, 2024, at 9:10 am EST. A live audio webcast of the presentation will be accessible through the 'Investors' section of AtriCure's website.

AtriCure reported strong Q3 2024 financial results with worldwide revenue reaching $115.9 million, up 17.9% year-over-year. U.S. revenue grew 16.8% to $95.5 million, while international revenue increased 23.3% to $20.5 million. The company achieved 20% growth in U.S. open appendage management devices and generated positive cash flow of $16.3 million. Gross profit was $86.8 million with a 74.9% margin. The company updated its full-year 2024 revenue guidance to $459-462 million, representing 15-16% growth, and maintained its Adjusted EBITDA guidance of $26-29 million.

AtriCure (Nasdaq: ATRC), a company specializing in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 5:00 pm Pacific Standard Time. A live audio webcast of the presentation will be accessible through the Investors section of AtriCure's website.

AtriCure, Inc. (Nasdaq: ATRC) has launched the cryoSPHERE MAX™ cryoablation probe, an upgraded device for Cryo Nerve Block™ therapy (cryoNB). The new probe features a larger 10 mm ball tip with 60% more surface area than previous models, enabling 50% reduced freeze times compared to the first-generation probe. Key improvements include:

- Reduced recommended ablation time to 60 seconds per targeted nerve
- Enhanced insulation and Nitrous Oxide gas utilization
- Improved tactile tissue feedback and real-time temperature monitoring
- Larger ice ball formation and greater heat extraction

These advancements aim to optimize efficiency, reduce total operative time, and improve gas utilization in post-operative pain management procedures.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the results.

Interested parties can register for the conference call online using the provided link. Registration is recommended more than 15 minutes before the call starts. Both live and replay versions of the audio webcast will be available on AtriCure's investor relations website.

AtriCure, Inc. (Nasdaq: ATRC) has received CE-Mark approval to sell the EnCompass® Clamp in European Union countries. This regulatory approval marks a significant expansion of AtriCure's product line internationally. The EnCompass Clamp, which received FDA 510(K) clearance and was launched in the United States in 2022, provides a simpler and faster approach to ablating the heart in open-chest procedures.

Key features of the EnCompass Clamp include:

• Ability to perform comprehensive epicardial ablation of the left atrium in minutes
• Parallel closure, uniform pressure, and custom power using Synergy radiofrequency (RF)
• Magnetic guide for easier placement and more efficient procedures
• Design that fits cardiac anatomy, supporting surgical ablation in procedures like CABG and AVR

AtriCure estimates approximately 400,000 cardiac surgeries occur annually in the European Union, representing a significant market opportunity for the EnCompass Clamp.